Regulatory reforms have made the UK a more attractive location to test candidate cancer medicines with efforts to reduce approval times being a key driver.<\/p>\n
This is according to new research<\/a>, which examined cancer trials conducted in the UK since 2000 and concluded that regulatory changes over the period have had a positive impact.<\/p>\n \u201cFrom 2000 to 2025, the UK clinical trials setting has evolved into a system that has adapted to global research demands. While transitional challenges emerged in the past decade, the UK has transformed toward a modernized, risk-proportionate, and globally applicable regulatory model,\u201d the authors wrote.<\/p>\n In particular, the authors cited efforts to accelerate clinical trial approvals as a success, explaining, \u201cTrial approval speed has improved from 118.9 days in July 2023 to 29 days in October 2025.\u201d<\/p>\n The authors also highlighted the Medicines and Healthcare Products Regulatory Agency\u2019s (MHRA) decision to allow sponsors to seek approval online\u2014through the IRAS system<\/a>, introduced in 2022\u2014as a positive move.<\/p>\n